Supportive Care in Cancer

, Volume 12, Issue 3, pp 191–196

Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal follow-up

  • Ming-Shen Dai
  • Pei-Fen Wu
  • Jang-Jih Lu
  • Rong-Yaun Shyu
  • Tsu-Yi Chao
Original Article


Reactivation of hepatitis B virus (HBV) after cytotoxic chemotherapy is a serious problem, and it occurred to 41% of breast cancer patients carrying HBV. Previous studies have demonstrated that lamivudine was effective for HBV flare-up during cytotoxic chemotherapy. We aimed to monitor the HBV status of breast cancer patients undergoing chemotherapy with preemptive lamivudine over time. Six breast cancer patients carrying hepatitis B surface antigen (HBsAg) were monitored during chemotherapy, five in the adjuvant setting and one with metastatic disease. Preemptive lamivudine was given throughout the chemotherapy course. HBsAg, HBV envelope antigen (HBeAg), anti-HBV envelope antibody (HBe Ab), serial serum alanine transaminase (ALT), quantitative HBV viral DNA analysis, and HBV DNA precore promoter and precore sequence were monitored. One patient carried wild type and the other five precore mutant strain of HBV by examination of HBV sequence in precore promoter and precore region. No evident HBV reactivation developed, and all patients tolerated lamivudine well. During the 6-to-8-month follow-up after cessation of cytotoxic therapy and withdrawal of lamivudine, serum ALT remained unchanged, although an increase of HBV DNA levels in four patients was found. No emergence of the tyrosine-methionine-aspartate-aspartate (YMDD) lamivudine-selective resistant strain was observed in the six patients. Preemptive use of lamivudine can effectively prevent reactivation of HBV in breast cancer patients receiving postoperative adjuvant chemotherapy. Lamivudine can be discontinued safely without emergence of lamivudine-resistant HBV strain or rebound HBV flare-up. The candidate for the use of preemptive lamivudine in HBV carriers who need short-term chemotherapy remained to be investigated.


Lamivudine Prophylactic treatment Hepatitis B virus reactivation Breast cancer 


  1. 1.
    Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G (1999) Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumor. Br J Cancer 81:69–74PubMedGoogle Scholar
  2. 2.
    Allen MI, Deslauriers M, Andrews CW et al (1998) Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670–1677PubMedGoogle Scholar
  3. 3.
    Al-Taie OH, Mork H, Gassel AM, Wilhelm M, Weissbrich B, Scheurlen M (1999) Prevention of hepatitis B flare-up during chemotherapy using Lamivudine: case report and review of literature. Ann Hematol 78:247–249PubMedGoogle Scholar
  4. 4.
    Beasley RP, Hwang LY, Lin CC, Leu ML, Stevens CE, Szmuness W et al (1982) Incidence of hepatitis B infection in preschool children in Taiwan. J Infect Dis 146:198–204PubMedGoogle Scholar
  5. 5.
    Cheng AL (1996) Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin’s lymphoma [letter]. Blood 87:1202Google Scholar
  6. 6.
    Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN (1998) Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin’s lymphoma. Ann Oncol 9:385–387PubMedGoogle Scholar
  7. 7.
    Dai MS, Lu CC, Chen YC, Peng CL, Chao TY (2001) Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients. Cancer 92:2927–2932PubMedGoogle Scholar
  8. 8.
    Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z (1999) Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256–1263PubMedGoogle Scholar
  9. 9.
    Gilson RJC, Chopra KB, Newell AM et al (1999) A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat 6:387–395PubMedGoogle Scholar
  10. 10.
    Honkoop P, De Man RA, Heijtink RA, Schalm SW (1995) Hepatitis B reactivation after lamivudine. Lancet 346:1156–1157PubMedGoogle Scholar
  11. 11.
    Kao JH, Chen PJ, Lai MY, Chen DS (2000) Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118:554–559PubMedGoogle Scholar
  12. 12.
    Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Liang TJ, Hoofnagle JH (2000) Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32(4):828–834PubMedGoogle Scholar
  13. 13.
    Lau GKK, Leung YH, Fong DYT, Au WY, Kwong YL, Lie A, Hou JL, Wen YM, Nanj A, Liang R (2002) High hepatitis B virus DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic stem cell transplantation. Blood 99:2324–2330PubMedGoogle Scholar
  14. 14.
    Lau JYN, Lai CL, Lin HJ, Lok ASF, Liang RHS, Wu PC, Chan TK, Todd D (1989) Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Quarterly J Med 270:911–917Google Scholar
  15. 15.
    Liang R, Lau GKK, Kwong YL (1999) Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 17:394–398PubMedGoogle Scholar
  16. 16.
    Liang RHS, Lok ASF, Lai CL, Chan TK, Todd D, Chiu EKW (1990) Hepatitis B infection in patients with lymphomas. Hematol Oncol 8:261–270PubMedGoogle Scholar
  17. 17.
    Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL (2002) Lamivudine for the treatment of hepatitis B reactivation following chemotherapy for non-Hodgkin’s lymphoma. Br J Haematol 116:166–169PubMedGoogle Scholar
  18. 18.
    Markovic S, Drozina G, Bovk M, Fidler-Jenko M (1999) Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 46:2925–2930PubMedGoogle Scholar
  19. 19.
    Nevens F, Main J, Honkoop P, et al. (1997) Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 113:1258–1263Google Scholar
  20. 20.
    Nishizono A, Kohno K, Takita-Sonoda Y, Hiraga M, Terao H, Fujuoka T, Nasu M, Mifune K (1997) Sequential analyses of the mutations in the core upstream and precore regions of hepatitis B virus genome in anti-HBe positive-carriers developing acute exacerbation. J Med Virology 53:266–272Google Scholar
  21. 21.
    Rizzetto M (2002) Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J Med Virology 66:435–451Google Scholar
  22. 22.
    Rizzetto M, Volpes R, Smedile A (2000) Response of precore mutant chronic hepatitis B infection to lamivudine. J Med Virology 61:398–402Google Scholar
  23. 23.
    Rossi G, Pelizzari A, Motta M, Puoti M, Ematologia S (2001) Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 115:58–62PubMedGoogle Scholar
  24. 24.
    Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G (2000) Long-term follow-up of patients with anti-HBe/HBV-DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatology 32:300–306Google Scholar
  25. 25.
    Sato T, Kato J, Kawanishi J, Kogawa K, Ohya M, Sakamaki S, Niitsu Y (1997) Acute exacerbation of hepatitis due to reactivation of hepatitis B virus with mutation in the core region after chemotherapy for malignant lymphoma. J Gastroenterol 32:668–671PubMedGoogle Scholar
  26. 26.
    Silvestri F, Ermacora A, Sperotto A, et al. (2000) Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol 108:394–396CrossRefPubMedGoogle Scholar
  27. 27.
    Steinberg JL, Yeo W, Zhong S, Chan JYH, Tam JS, Chan PKS, Leung NWY, Johnson PJ (2000) Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumors: Precore/core mutations may play an important role. J Med Virology 60:249–255Google Scholar
  28. 28.
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kpeteman NM, Tyrrel DL (1996) Mutation in HBV RNA dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714–717PubMedGoogle Scholar
  29. 29.
    Yeo W, Steinberg JL, Tam JS, Chan PK, Leung NW, Lam KC, Mok TS, Johnson PJ (1999) Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virology 59:263–269Google Scholar
  30. 30.
    Yeo W, Chan PKS, Chan HLY, Mo FKF, Johnson PJ (2001) Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol 65:473–477PubMedGoogle Scholar
  31. 31.
    Yeo W, Chan PKS, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ (2003) Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70:553–561PubMedGoogle Scholar
  32. 32.
    Yeo W, Zhong S, Chan PK, Ho WM, Wong HT, Chan HS, Johnson PJ (2000) Sequence variations of precore/core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy. J Viral Hepatol 7:448–458Google Scholar
  33. 33.
    Yoshiba M, Sekiyama K, Sugata F, Okamoto H, Yamamoto K, Yotsumoto S (1992) Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment. Dig Dis Sci 37:1253–1259PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Ming-Shen Dai
    • 1
  • Pei-Fen Wu
    • 1
  • Jang-Jih Lu
    • 3
  • Rong-Yaun Shyu
    • 2
  • Tsu-Yi Chao
    • 1
  1. 1.Division of Hematology/Oncology, Department of MedicineTri-Service General Hospital, National Defense Medical CenterNeihu 114, TaipeiTaiwan
  2. 2.Division of Gastroenterology, Department of MedicineTri-Service General Hospital, National Defense Medical CenterNeihu 114, TaipeiTaiwan
  3. 3.Department of Clinical PathologyTri-Service General Hospital, National Defense Medical CenterNeihu 114, TaipeiTaiwan

Personalised recommendations